Hims & Hers Health would discontinue Apostrophe, its personalized acne treatments dermatology business, the company said on ...

Hims and Hers is shutting down Apostrophe, the skincare company it acquired in 2021, after a tumultuous month for the public ...

Telehealth personalized care company Hims & Hers shuttered a central part of its dermatology offering, skincare brand Apostrophe, to "simplify" its dermatology offerings and operation | Hims & Hers ...

Roller-coaster healthcare stock Hims & Hers Health ( HIMS -1.34%), whose stock got devastated last week by worries that it ...

Hims & Hers generated $1.5 billion in revenue in 2024, reflecting a 69% year-over-year increase. See why I rate HIMS stock a ...

Hims & Hers Health has called time on Apostrophe, its personalised acne treatments business. The San Francisco-based ...

After the FDA removed semaglutide injection products from a shortage list, compounders like Hims have 60-90 days to stop ...

Hims & Hers Health shares were headed for their biggest single-day plunge as Wall Street analysts questioned the telehealth provider's lofty sales forecast on Tuesday amid looming restrictions on ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

The message suggested visiting Hims & Hers to pursue further skincare treatment. "After careful consideration, we are discontinuing Apostrophe to simplify our dermatology products and operations ...

(Reuters) -Hims & Hers Health would discontinue Apostrophe, its personalized acne treatments dermatology business, the company said on Friday. Apostrophe is being shut down to "simplify its ...